Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026Leukemia & lymphoma/Leukemia and lymphomaOpen Access

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMayur NarkhedeSBSibel BlauAPAaron Peevyhouse

Discussion

Loading...

Member takes

Overview

Retrospective observational study compares hypertension and treatment failure in treatment-naïve CLL/SLL on acalabrutinib versus ibrutinib.

Key Points

  • To compare time to new/worsening hypertension and treatment failure between acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.
  • Retrospective observational study using electronic medical records from ONCare Alliance.
  • Included adults (N=454) with treatment-naïve CLL/SLL on acalabrutinib or ibrutinib monotherapy.
  • Primary endpoint was time to new/worsening hypertension; secondary was time to treatment failure with median follow-up of 28 months.
  • Acalabrutinib had fewer discontinuations due to intolerability at 19.4% compared to 46.7% for ibrutinib (p<.001).
  • Acalabrutinib significantly reduced the risk of new/worsening hypertension (HR 0.27; 95% CI, 0.14–0.55; p<.001).
  • Acalabrutinib prolonged time to treatment failure (HR 0.42; 95% CI, 0.31–0.56; p<.001).

Cite This Study

Narkhede et al. (2026) studied this question.

synapsesocial.com/papers/6a3f67aaaea7db3c1953efbchttps://doi.org/10.1080/10428194.2026.2687635
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib/acalabrutinib in chronic lymphocytic leukemia2025 · 7 citations
  2. 2Adverse event profiles of acalabrutinib and zanubrutinib in chronic lymphocytic leukemia: A real-world comparison2025 · 1 citations
  3. 3Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis2025
  4. 4Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting2025
  5. 5Real-world zanubrutinib treatment patterns in CLL/SLL among a curated sample of US community oncology patients with prior acalabrutinib therapy2025 · 1 citations